semaglutide ckd approval just got FDA-approved for kidney disease. This changes everything., January 2025. The FDA approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in Novo Nordisk secures FDA approval

The Desir et al

Room temperature or slightly warm water often sits better on a sensitive stomach than ice cold water

Conclusion GLP-1 receptor agonists have emerged as powerful agents that improve metabolic health lowering blood sugar, inducing weight loss, and reducing cardiovascular risk in patients with diabetes or obesity

However, a 2022 study found that those who take semaglutides regained two-thirds of their prior weight loss after a year of being off the drug

Retatrutide's proposed mechanism of action involves GLP-1 receptor activation to slow gastric emptying and promote satiety, GIP receptor activation to support insulin secretion and adipose tissue regulation, and glucagon receptor agonism, which in trial settings has been associated with increased energy expenditure and lipolysis